The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Feb. 26, 2016
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventors:

Sheng Wei, Tampa, FL (US);

Alan List, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/341 (2006.01); A61K 31/454 (2006.01); A61K 31/711 (2006.01); A61K 31/12 (2006.01); A61K 31/64 (2006.01); A61K 31/713 (2006.01); A61K 31/34 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/341 (2013.01); A61K 31/12 (2013.01); A61K 31/34 (2013.01); A61K 31/454 (2013.01); A61K 31/64 (2013.01); A61K 31/7088 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); C12N 15/1137 (2013.01); G01N 33/57426 (2013.01); G01N 33/6872 (2013.01); A61P 35/00 (2018.01); C12N 2310/14 (2013.01); G01N 2333/4727 (2013.01); G01N 2333/96466 (2013.01); G01N 2800/7095 (2013.01);
Abstract

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of an inflammasome inhibitor. Also disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the subject to detect inflammasome activation, wherein an increase in inflammasome activation in the sample compared to a control is an indication of MDS in the subject. In some embodiments, the method involves assaying a sample from the subject to detect s100A9 protein levels, wherein an increase in s100A9 protein levels in the sample compared to a control is an indication of MDS in the subject. The disclosed methods can further involve treating the subject for MDS if an increase in inflammasome activation and/or s100A9 levels are detected.


Find Patent Forward Citations

Loading…